ArticleNPJ Regenerative medicine2019
Trends in clinical trials for stroke by cell therapy: data mining ClinicalTrials.gov and the ICTRP portal site.
Article in NPJ Regenerative medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Stem cell-based interventions for the treatment of stroke in newborn infants.The Cochrane database of systematic reviews · 2023Pooled it
- How neural stem cell therapy promotes brain repair after stroke.Stem cell reports · 2025Review
- Brain repair mechanisms after cell therapy for stroke.Brain : a journal of neurology · 2024Review
- Stiff Hydrogel Encapsulation Retains Mesenchymal Stem Cell Stemness for Regenerative Medicine.Matter · 2024Article
- Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov.Translational psychiatry · 2024Review
- Stem Cell Therapy for Repair of the Injured Brain: Five Principles.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2024Article
- Stem cell therapy: a new hope for stroke and traumatic brain injury recovery and the challenge for rural minorities in South Carolina.Frontiers in neurology · 2024Review
- The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs.Frontiers in pharmacology · 2023Article
- Present and future avenues of cell-based therapy for brain injury: The enteric nervous system as a potential cell source.Brain pathology (Zurich, Switzerland) · 2022Review
- Clinical trials of stem cell-based therapies for pediatric diseases: a comprehensive analysis of trials registered on ClinicalTrials.gov and the ICTRP portal site.Stem cell research & therapy · 2022Article
- The Beneficial Potential of Genetically Modified Stem Cells in the Treatment of Stroke: a Review.Stem cell reviews and reports · 2022Review
- Mesenchymal Stem Cells for Neurological Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Automated Identification of Common Disease-Specific Outcomes for Comparative Effectiveness Research Using ClinicalTrials.gov: Algorithm Development and Validation Study.JMIR medical informatics · 2021Article
- Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis.NPJ Regenerative medicine · 2020Article
- Bidirectional Enhancement of Cell Proliferation Between Iron Oxide Nanoparticle-Labeled Mesenchymal Stem Cells and Choroid Plexus in a Cell-Based Therapy Model of Ischemic Stroke.International journal of nanomedicine · 2020Article
- Analysis of Current Status of Clinical Trial Registrations in Andrological Diseases: Insights from ClinicalTrials.gov and ICTRP Databases.American journal of men's healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Definitive treatment of stroke constitutes an important thesis of regenerative medicine in the cerebrovascular field. However, to date, no cell therapy products for stroke are yet on the market. In this study, we examined the clinical research trends related to cell therapy products in the stroke field based on data obtained from the ClinicalTrials.gov website and International Clinical Trials Research Platform (ICTRP) portal site. These data do not offer results of clinical trials comprehensively but provide information regarding various attributes of planned clinical trials including work in progress. We selected 78 cell therapy studies related to the field of stroke treatment from ClinicalTrial.gov and ICTRP. These were analyzed according to, e.g., the reporting countries, origin (autologous or allogeneic), of cell used, cell types and source organs, the progress of translational phases, target phase of the disease (acute or chronic stroke), and route of administration. This analysis revealed a trend whereby in the acute phase, mesenchymal stem cells were administered intravenously at a relatively higher dose, whereas in the chronic phase a small number of cells were administered intracranially. Only two randomized controlled Phase III studies with over 100 patients are registered, but none of them has been completed. Thus, cell therapy against stroke appears to constitute a premature area compared with cartilage repair as assessed in our previous report. In addition, tracking by means of the ID number of each trial via PubMed revealed that 44% of clinical studies in this field have corresponding published results, which was also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.